Prescription drug costs remain a central national health care issue as federal officials and drugmakers continue to battle over how much Americans pay compared with patients in other developed countries. That debate sharpened again on August 31, 2026, when President Donald Trump announced a fresh set of voluntary pricing agreements with pharmaceutical manufacturers. The White House said the move expands its most-favored-nation drug pricing strategy, which aims to bring some U.S. prices closer to the lowest levels paid abroad.
Trump adds nine manufacturers to pricing program
President Donald Trump announced agreements with nine additional pharmaceutical manufacturers on August 31, 2026, according to a White House fact sheet released the same day. The administration said the new deals were reached with Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. Axios also reported Monday that the agreements involved midsize manufacturers added to the administration’s existing drug pricing framework.
The White House said those additions bring the total number of manufacturers with most-favored-nation, or MFN, agreements to 26, covering 89% of the branded drug market. Under that model, the administration says participating companies agree to lower U.S. prescription prices in line with the lowest prices paid by other developed nations. The White House has framed the agreements as voluntary commitments rather than a new law or regulation imposed across the market.
What remains unclear is the full product-by-product impact. The administration did not release a comprehensive list Monday of every drug included in the new round of agreements or the exact price cuts attached to each medicine. The White House has previously tied the broader initiative to TrumpRx.gov, a federal pricing portal launched on February 5, 2026, for patients seeking lower prices on selected brand-name medicines.
Because the August 31 announcement was national in scope, the immediate state-by-state impact is still not fully mapped out. The White House said earlier MFN-style agreements were intended to reach Medicaid programs, Medicare patients and consumers using TrumpRx.gov, but Monday’s announcement did not include a detailed breakdown of how the nine new deals will affect individual states. No public document released with the announcement provided a state-specific list of covered drugs, pharmacies or patient eligibility rules.
That means residents in any given state, including large Medicaid markets, may not yet know which prescriptions will reflect lower pricing first. The administration has not released a full list of affected state programs, participating pharmacies or plan-level implementation dates connected specifically to this latest round. It also has not said whether rollout timing will differ between Medicaid, cash-pay buyers and other channels.
Still, the White House has argued that the reach is broad because the 26 agreements now touch most of the branded drug market. In earlier statements this year, the administration said the policy had already helped push prescription drug prices down 3.9% since Trump took office and had produced more than $10 billion in Veterans Affairs pharmaceutical savings in the current fiscal year. Those figures were cited by the White House, and independent program-by-program verification was not included in Monday’s announcement.
The Trump administration has consistently said the policy is aimed at narrowing the gap between U.S. drug prices and lower prices overseas. In White House research materials published in May, officials said the MFN framework was designed to address what they described as major differences in drug prices among developed countries, while also preserving access to innovative medicines. The same materials said the administration was seeking both voluntary agreements and eventual congressional action to lock the policy into law.
The White House has also connected the strategy to a wider health policy agenda. Administration releases this year said TrumpRx.gov was created to give patients direct access to discounted prices, while a broader legislative package called the Great Healthcare Plan would codify parts of the savings approach, lower insurance premiums and expand price transparency. In that sense, Monday’s announcement fits into a longer campaign rather than a standalone action.
For patients, the practical takeaway is narrower than the headline. Some branded medicines may become less expensive through Medicaid, federal programs or cash-price channels tied to TrumpRx.gov, but the administration has not yet published a complete drug list for this newest set of agreements. Until that information is released, customers and state agencies can confirm only that the program expanded on August 31, 2026, and that federal officials say additional pricing details are expected as implementation continues.